Stine Gry Kristensen1, Yu Wakimoto2, Lotte Berdiin Colmorn3, Margit Dueholm4, Susanne Elisabeth Pors5, Kirsten Tryde Macklon3, Linn Salto Mamsen5, Dmitry Nikiforov5, Jesús Cadenas5, Vinnie Hornshøj Greve4, Anne-Mette Bay Bjørn6, Mikkel Rosendahl7, Anette Tønnes Pedersen7, Anders Nyboe Andersen3, Jens Fedder8, Erik Ernst6, Claus Yding Andersen5. 1. Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. Electronic address: stine.gry.kristensen@regionh.dk. 2. Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark; Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan. 3. The Fertility Clinic, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. 4. Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark. 5. Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. 6. Department of Gynecology and Obstetrics, Horsens Regional Hospital, Horsens, Denmark. 7. Department of Gynecology and Obstetrics, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. 8. Centre of Andrology and Fertility Clinic, Odense University Hospital and Research Unit of Human Reproduction, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Abstract
OBJECTIVE: To evaluate the use of cryopreserved ovarian tissue in the Danish fertility preservation cohort. DESIGN: Retrospective cohort study. SETTING: University hospitals and fertility clinics. PATIENT(S): Ovarian tissue cryopreservation (OTC) was performed for 1,186 Danish girls and women from 1999-2020, of whom 117 subsequently underwent ovarian tissue transplantation (OTT). Subgroup 1 included 759 patients with a follow-up period of >5 years. Out of these, OTT rates were further analyzed for those patients who were alive and aged >24 years in July 2020 (subgroup 2; n = 554). INTERVENTION(S): OTC and OTT. MAIN OUTCOME MEASURE(S): OTT, death, donation of tissue. RESULT(S): In subgroup 1, 14% of the patients had undergone OTT, 18% had died, 9% had donated their tissue for research, and 59% still had their tissue stored. In subgroup 2, 19% had undergone OTT and for most diagnoses the OTT rates ranged from 15% to 22% with benign hematologic diseases having the highest OTT rate (35%). On the basis of the entire cohort, stratified age analysis indicated that women aged ≥30 years at OTC were more likely to return for OTT than women aged 18-29 years at OTC; mean storage times were 3.7 and 3.6 years, respectively. Only 4% of the girls aged <18 years at OTC had undergone OTT. CONCLUSION(S): The OTT rates depended on the diagnosis, age at OTC, and follow-up time. Specific criteria are needed for reporting and comparing OTT rates. Six out of 10 patients still had their cryopreserved tissue stored and longer follow-up is needed, especially for younger girls.
OBJECTIVE: To evaluate the use of cryopreserved ovarian tissue in the Danish fertility preservation cohort. DESIGN: Retrospective cohort study. SETTING: University hospitals and fertility clinics. PATIENT(S): Ovarian tissue cryopreservation (OTC) was performed for 1,186 Danish girls and women from 1999-2020, of whom 117 subsequently underwent ovarian tissue transplantation (OTT). Subgroup 1 included 759 patients with a follow-up period of >5 years. Out of these, OTT rates were further analyzed for those patients who were alive and aged >24 years in July 2020 (subgroup 2; n = 554). INTERVENTION(S): OTC and OTT. MAIN OUTCOME MEASURE(S): OTT, death, donation of tissue. RESULT(S): In subgroup 1, 14% of the patients had undergone OTT, 18% had died, 9% had donated their tissue for research, and 59% still had their tissue stored. In subgroup 2, 19% had undergone OTT and for most diagnoses the OTT rates ranged from 15% to 22% with benign hematologic diseases having the highest OTT rate (35%). On the basis of the entire cohort, stratified age analysis indicated that women aged ≥30 years at OTC were more likely to return for OTT than women aged 18-29 years at OTC; mean storage times were 3.7 and 3.6 years, respectively. Only 4% of the girls aged <18 years at OTC had undergone OTT. CONCLUSION(S): The OTT rates depended on the diagnosis, age at OTC, and follow-up time. Specific criteria are needed for reporting and comparing OTT rates. Six out of 10 patients still had their cryopreserved tissue stored and longer follow-up is needed, especially for younger girls.
Authors: L M Ataman; M M Laronda; M Gowett; K Trotter; H Anvari; F Fei; A Ingram; M Minette; C Suebthawinkul; Z Taghvaei; M Torres-Vélez; K Velez; S K Adiga; A Anazodo; L Appiah; M T Bourlon; N Daniels; M M Dolmans; C Finlayson; R B Gilchrist; V Gomez-Lobo; E Greenblatt; J A Halpern; K Hutt; E K Johnson; K Kawamura; M Khrouf; D Kimelman; S Kristensen; R T Mitchell; M B Moravek; L Nahata; K E Orwig; M E Pavone; D Pépin; R Pesce; G P Quinn; M P Rosen; E Rowell; K Smith; C Venter; S Whiteside; S Xiao; M Zelinski; K N Goldman; T K Woodruff; F E Duncan Journal: J Assist Reprod Genet Date: 2022-07-23 Impact factor: 3.357